Clinical Trials

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT02761057 2025-01-13

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

364 enrolled 89 charts 1 FDA

152 enrolled 19 charts

Genitourinary

Carcinoma, Renal Cell

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02679170 2024-08-09

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

692 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT01606878 2024-01-05

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

46 enrolled 24 charts

CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

NCT02223819 2023-12-06

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

34 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

549 enrolled 28 charts

ALK-positive NSCLC

NCT03088930 2022-02-11

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

3 enrolled 7 charts

275 enrolled 23 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT02510001 2021-07-13

MErCuRIC1

82 enrolled 36 charts

Gastrointestinal

Colorectal Neoplasms

NCT02574078 2021-05-06

CheckMate370

Phase 1/2 Completed

341 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT01945021 2021-02-21

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

129 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01639001 2020-12-08

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Phase 3 Completed

207 enrolled 29 charts

Carcinoma, Non-Small-Cell Lung

NCT01999972 2020-09-24

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

122 enrolled 24 charts 2 FDA

50 enrolled 29 charts

Tumor-Agnostic

Carcinoma

NCT00939770 2020-06-09

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Phase 1/2 Completed

CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

NCT01597258 2019-09-13

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

2,029 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT01576406 2018-10-25

Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

88 enrolled 44 charts

Advanced Cancer

NCT00932451 2017-01-13

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

1,069 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT00965731 2015-10-28

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

27 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01121575 2015-10-28

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

70 enrolled 50 charts